BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31173390)

  • 1. Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.
    Li Y; Shi Z; Jules J; Chen S; Kesterson RA; Zhao D; Zhang P; Feng X
    J Bone Miner Res; 2019 Oct; 34(10):1938-1951. PubMed ID: 31173390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.
    Jules J; Wang S; Shi Z; Liu J; Wei S; Feng X
    J Biol Chem; 2015 Sep; 290(39):23738-50. PubMed ID: 26276390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.
    Jules J; Shi Z; Liu J; Xu D; Wang S; Feng X
    J Biol Chem; 2010 Nov; 285(48):37427-35. PubMed ID: 20870724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB.
    Zhang P; Liu J; Xu Q; Harber G; Feng X; Michalek SM; Katz J
    J Biol Chem; 2011 Jul; 286(27):24159-69. PubMed ID: 21566133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice.
    Yang X; Gao W; Wang B; Wang X; Guo H; Xiao Y; Kong L; Hao D
    J Cell Biochem; 2017 Dec; 118(12):4479-4486. PubMed ID: 28464271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection of RANKL-primed RAW-D macrophages with Porphyromonas gingivalis promotes osteoclastogenesis in a TNF-α-independent manner.
    Kukita A; Ichigi Y; Takigawa I; Watanabe T; Kukita T; Miyamoto H
    PLoS One; 2012; 7(6):e38500. PubMed ID: 22723864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis.
    Cheng J; Liu J; Shi Z; Jules J; Xu D; Luo S; Wei S; Feng X
    J Interferon Cytokine Res; 2012 Jan; 32(1):34-45. PubMed ID: 22142221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.
    Liu W; Xu D; Yang H; Xu H; Shi Z; Cao X; Takeshita S; Liu J; Teale M; Feng X
    J Biol Chem; 2004 Dec; 279(52):54759-69. PubMed ID: 15485878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hemoglobin receptor protein of porphyromonas gingivalis inhibits receptor activator NF-kappaB ligand-induced osteoclastogenesis from bone marrow macrophages.
    Fujimura Y; Hotokezaka H; Ohara N; Naito M; Sakai E; Yoshimura M; Narita Y; Kitaura H; Yoshida N; Nakayama K
    Infect Immun; 2006 May; 74(5):2544-51. PubMed ID: 16622189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
    Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
    J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
    Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
    Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling.
    AlQranei MS; Senbanjo LT; Aljohani H; Hamza T; Chellaiah MA
    BMC Immunol; 2021 Mar; 22(1):23. PubMed ID: 33765924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.